June 18, 2009 - Calypso Medical Technologies announced the publication of three new studies investigating the role of the Calypso 4D Localization System in guiding immediate adjustments to radiation delivery in response to tumor motion, a concept known as real-time adaptive radiation treatment.

The three studies were part of a multi-institutional academic and industrial collaboration between Washington University in St. Louis, Stanford University in Palo Alto, Calif., Swedish Cancer Institute in Seattle, Varian Medical Systems and Calypso Medical. The studies appear in the International Journal of Radiation Oncology, Biology, Physics (http://www.redjournal.org). The findings indicate that substantial treatment benefits may be realized in the way radiation therapy is delivered for all tumor sites, including fast moving, difficult-to-treat tumors, such as those in the lungs.
These studies include:
"Evaluation of Linear Accelerator Gating with Real-Time Electromagnetic Tracking." Ryan L. Smith, et al. July 2009, vol. 74, issue 3, pp. 920-927.

"Integration of Real-Time Internal Electromagnetic Position Monitoring Coupled with Dynamic Multileaf Collimator Tracking: An Intensity-Modulated Radiation Therapy Feasibility Study." Ryan L. Smith, et al. July 2009, vol. 74, issue 3, pp. 868-875.

"Toward Submillimeter Accuracy in the Management of Intrafraction Motion: The Integration of Real-Time Internal Position Monitoring and Multileaf Collimator Target Tracking." Amit Sawant, et al. June 2009, vol. 74, issue 2, pp. 575-582.

"This research highlights the technical feasibility of integrating the Calypso System with advanced linear accelerator capabilities," according to Dr. Parag Parikh, M.D., assistant professor of radiation oncology and biomedical engineering at Washington University. "The work shows that Calypso electromagnetic tracking can lead to more than just tumor positioning, it can facilitate novel methods of addressing organ motion and can enable highly accurate treatment for moving targets."

The first study, conducted at Washington University and Swedish Cancer Institute, demonstrates how the Calypso System is integrated with the linear accelerator - the equipment used to deliver radiation to cancerous tumors - to gate the radiation beam when the tumor motion exceeded certain thresholds. The ability to automatically to do gating is demonstrated utilizing internal information that reflects how the tumor is moving rather than relying on external markers. Gating the beam based on actual tumor motion improves the quality of treatment that the patient receives and is an important capability that only the Calypso System can provide.

"When tumor motion is left unchecked, it can limit the quality of treatments we can provide. Gating allows us to address motion, reduce the radiation damage to critical structures, and open up the possibility of pursuing novel treatment paradigms like dose escalation," said Dr. David Shepard, director of medical physics at Swedish Cancer Institute.

As Dr. Paul Keall, associate professor and director of the radiation physics division at Stanford said, "The obvious solution is to have the radiation beam follow the moving target. In our multi-institutional work, Calypso tracking measurements were used to redirect the treatment beam in real-time as the target moved."

The other studies conducted at Stanford University and Washington University highlight that Calypso System data can be used to adapt treatment by guiding the multi-leaf collimator - the part of the linear accelerator used to shape the radiation beam - thereby moving it in real time. Tracking the tumor motion based on Calypso System data will enable radiation treatment to be delivered to moving targets with a higher degree of accuracy and confidence. "This technological leap to sub-millimeter accuracy opens new frontiers for radiotherapy and will allow us to rethink both the normal structures spared and targets defined during radiation treatments," said Dr. Keall.

The ability to track tumor motion is a critical component in adapting radiation therapy as it assures the clinician and the patient that radiation is delivered to the cancerous tissue while sparing healthy tissue, thereby decreasing side effects of radiation therapy.

For more information: www.calypsomedical.com


Related Content

News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
Subscribe Now